Hypokalaemia: finding the cause and correcting it safely — the AU GP approach

Potassium is the dominant intracellular cation — roughly 98% of total body potassium sits inside cells. The narrow extracellular range of 3.5–5.0 mmol/L is tightly regulated, and small shifts drive large consequences for muscle function, cardiac conduction, and renal physiology. Hypokalaemia — serum potassium below 3.5 mmol/L — is one of the most common electrolyte abnormalities encountered in Australian general practice, appearing most frequently as a side effect of diuretic therapy or after a bout of gastroenteritis.

The clinical challenge is twofold: deciding how urgently to act (mild versus emergency), and tracing the cause so replacement doesn’t become a revolving door. Diuretics are not the only answer. Eating disorders, primary aldosteronism, DKA, and magnesium deficiency each create a distinct management pathway, and missing them means potassium keeps falling despite supplementation.

A. Core clinical — the AU general-practice framework

Severity tiers

The first decision is severity, because it drives the speed of response:

Level	Potassium	Action
Mild	3.0–3.4 mmol/L	Oral correction outpatient; cause review
Moderate	2.5–2.9 mmol/L	Higher-dose oral; close monitoring; consider IV
Severe	<2.5 mmol/L	Emergency: ambulance + IV potassium + ECG
Any level + ECG changes / symptoms / arrhythmia / digoxin on board	—	Emergency regardless of number

History to take

eTG Renal and AMH emphasise a structured cause-finding approach before deciding on treatment:

• Current medications — diuretic type, dose, and duration; fludrocortisone or corticosteroids; high-dose beta-2 agonist (nebulised salbutamol, theophylline); amphotericin B; hydroxychloroquine
• Gastrointestinal symptoms — vomiting frequency, diarrhoea, recent gastroenteritis, inflammatory bowel disease, laxative use
• Eating and weight — restriction, purging, laxative or diuretic abuse; BMI change; exercise patterns (diuretic abuse in athletes)
• Hypertension with low potassium — raises primary aldosteronism as a differential
• Endocrine history — Cushingoid features, thyroid symptoms (hyperthyroid-associated periodic paralysis)
• Diabetes — DKA with subsequent insulin treatment shifts potassium into cells; total-body potassium is depleted
• Episodic muscle paralysis — particularly after carbohydrate loading, exercise, or stress in young men of Asian descent (hypokalaemic periodic paralysis)
• Family history — Bartter or Gitelman syndrome, periodic paralysis
• Alcohol use — refeeding risk; concurrent poor nutrition
• Symptoms — muscle weakness, cramps, palpitations, fatigue, polyuria, constipation

Examination

• Blood pressure — hypertension plus hypokalaemia points toward mineralocorticoid excess; postural drop suggests volume depletion
• Volume status — mucous membranes, jugular venous pressure, peripheral oedema
• Muscle strength — proximal > distal weakness is the pattern; test arm abduction, leg lift, and squat-to-stand
• Reflexes — reduced in moderate-to-severe hypokalaemia
• Cushingoid features — central obesity, striae, moon face, easy bruising
• Nutritional state — low BMI, parotid hypertrophy, and dental erosion in eating disorders
• ECG at the bedside — U waves (most characteristic), T-wave flattening, prolonged QT

Investigations

First-line investigations for any confirmed or suspected hypokalaemia (NPS MedicineWise):

• Repeat venous potassium to confirm (haemolysis during collection falsely elevates)
• Urea, electrolytes, creatinine, eGFR, magnesium, calcium, phosphate, bicarbonate, glucose — full metabolic picture
• ECG — mandatory; U waves and QT prolongation are severity markers
• Venous blood gas or arterial blood gas — acid-base status; metabolic alkalosis in vomiting and diuretics; metabolic acidosis in RTA and DKA
• Creatine kinase and urinalysis with microscopy — rhabdomyolysis screen in symptomatic patients
• 24-hour urinary potassium and chloride — distinguishes renal from extrarenal loss; urinary potassium >25 mmol/24h with hypokalaemia confirms renal wasting
• Aldosterone-to-renin ratio — when hypertension accompanies hypokalaemia (see Section B)
• TSH, free T4 — when periodic paralysis is suspected
• Morning cortisol — when Cushing’s syndrome is in the differential

Management — severity-graded

Mild (3.0–3.4 mmol/L), asymptomatic

Per eTG Renal:

1. Confirm with a repeat sample
2. Identify and address the underlying cause — reduce or substitute diuretic, treat vomiting or diarrhoea, cease eating-disorder behaviours with appropriate referral
3. Start oral potassium chloride — Slow-K or Span-K (600 mg = 8 mmol per tablet), typically one to three tablets two to three times daily (16–72 mmol/day in divided doses)
4. Replace magnesium if serum level is below 0.7 mmol/L — oral magnesium aspartate or citrate 200–400 mg daily
5. Dietary potassium advice as an adjunct: banana, potato, tomato, orange, beans, lentils, dried fruit, yoghurt
6. Recheck potassium in 2–7 days

Diuretic strategy: consider dose reduction, substitution with a potassium-sparing agent (amiloride combination such as Moduretic; spironolactone for heart failure or primary aldosteronism), or switching class to an ACE inhibitor or ARB.

Moderate (2.5–2.9 mmol/L), asymptomatic

• Higher-dose oral potassium chloride: 40–80 mmol/day in divided doses
• Always replete magnesium concurrently
• Consider intravenous potassium if vomiting prevents oral intake
• Refer to endocrinology if primary aldosteronism or Cushing’s is suspected
• Recheck within 48 hours

Severe (<2.5 mmol/L) or with ECG changes / symptoms / arrhythmia / digoxin

This is a medical emergency — call 000 and arrange transfer:

• Continuous ECG monitoring
• IV potassium chloride in normal saline: peripheral IV maximum 20 mmol/L concentration; central line maximum 40–60 mmol/L
• Maximum infusion rate 10–20 mmol/hour under continuous cardiac monitoring
• Never push undiluted potassium chloride — this causes cardiac arrest
• Concurrent IV magnesium sulfate
• Treat the underlying precipitant

B. The magnesium-first principle and primary aldosteronism

Magnesium must come first

Serum magnesium below 0.7 mmol/L accompanies hypokalaemia in approximately 40% of cases, and magnesium deficiency blocks renal potassium reabsorption through an incompletely understood tubular mechanism. The clinical consequence is that potassium supplementation is futile until magnesium is repleted.

Clinically, a potassium level that fails to rise despite adequate supplementation should trigger reassessment of magnesium. Loop diuretics deplete both minerals simultaneously, as does severe diarrhoea and chronic alcohol use. Magnesium depletion also independently prolongs the QT interval and increases arrhythmia risk — both concerns compound in the context of hypokalaemia.

Primary aldosteronism — the treatable HTN + low K combination

The Endocrine Society 2016 guideline recommends screening for primary aldosteronism in anyone with hypertension and unprovoked hypokalaemia. Estimates suggest primary aldosteronism accounts for 5–10% of treatment-resistant hypertension — a condition that is systematically underdiagnosed in Australian general practice.

Screening is performed with the aldosterone-to-renin ratio, ideally after a 2–4-week washout of interfering medications (ACE inhibitors, ARBs, beta-blockers, mineralocorticoid receptor antagonists) where this is safe. Confirmatory testing (saline infusion test, fludrocortisone suppression test) and subtype localisation (adrenal CT, adrenal vein sampling) are specialist-led. Treatment is with spironolactone or eplerenone for bilateral hyperplasia, or laparoscopic adrenalectomy for a unilateral adenoma.

Refeeding syndrome and DKA

In patients with chronic malnutrition — anorexia nervosa, alcoholism, prolonged illness — carbohydrate refeeding triggers an insulin surge that drives potassium, phosphate, and magnesium rapidly into cells. Refeeding syndrome produces severe combined electrolyte deficiency and can cause cardiac failure, arrhythmia, and respiratory compromise within hours of refeeding. Prevention requires slow caloric reintroduction with electrolyte supplementation and specialist oversight in high-risk patients.

In DKA, serum potassium may appear normal or elevated at presentation because acidosis shifts potassium extracellularly. However, total body potassium is usually severely depleted. Once insulin is started, potassium moves back into cells rapidly, and hypokalaemia can develop precipitously. Potassium replacement is started concurrently with insulin therapy in DKA management.

C. Diuretics, eating disorders, and medication review

The single most actionable step in most cases of hypokalaemia seen in Australian general practice is a thorough medication review. Thiazide diuretics — hydrochlorothiazide, chlorthalidone, and indapamide — are widely used for hypertension and cause chronic potassium and magnesium depletion through distal tubular action. Loop diuretics (furosemide) produce similar but more acute depletion.

Before prescribing long-term potassium supplementation, consider whether the diuretic dose can be reduced, replaced with a potassium-sparing agent, or substituted with a non-diuretic antihypertensive. AMH provides guidance on amiloride-hydrochlorothiazide combinations (Moduretic) and spironolactone dosing.

Recurrent unexplained hypokalaemia — particularly in a young woman with dental erosion, parotid enlargement, low BMI, or a history of restrictive eating — warrants a sensitive conversation about disordered eating. The RACGP and RANZCP guidelines support a non-judgemental eating-disorder screen as part of the medical evaluation. These patients may be self-administering diuretics or laxatives without disclosure.

Certain medications beyond diuretics cause hypokalaemia through specific mechanisms: high-dose nebulised salbutamol (beta-2 adrenergic stimulation); amphotericin B (direct distal tubular toxicity); high-dose corticosteroids (mineralocorticoid effect); licorice in excess quantities (carbenoxolone-like effect); hydroxychloroquine at high doses.

D. Australian operations

MBS items: Standard GP consultations use item 23 or item 36. ECG is claimable under item 11700. For patients with hypertension and suspected aldosteronism as part of a chronic disease framework, the GP Chronic Condition Management Plan item 965 and team-care arrangement item 967 may be applicable. Eating Disorders Plans item 90250 and above apply where eating disorder is the underlying cause.

PBS: Slow-K and Span-K (potassium chloride 600 mg tablets) are listed on the general schedule without authority. Oral magnesium preparations (aspartate, citrate, oxide) are general schedule. Spironolactone is general schedule; Authority Required (Streamlined) for primary aldosteronism. Eplerenone requires authority for heart failure post-myocardial infarction.

Safety-netting for patients: “Potassium keeps your heart and muscles working. Your level is low — we’ll find out why, and we’ll give you potassium tablets and check it again in a few days. Eat potassium-rich foods: banana, potato, orange, tomato, beans. If you feel your heart racing, notice muscle weakness, or feel unwell, please come back or go to an emergency department. Never stop your tablets without checking with your GP first.”

Consumer resources: HealthDirect — Low potassium; Better Health Channel; Kidney Health Australia for patients with concurrent CKD at kidney.org.au.

E. Special populations

Older adults and digoxin: Hypokalaemia potentiates digoxin toxicity by enhancing digoxin binding to myocardial sodium-potassium ATPase, causing arrhythmias at normally therapeutic digoxin concentrations. Any degree of hypokalaemia in a patient taking digoxin should be treated promptly, with a target of 4.0–4.5 mmol/L. Digoxin is less commonly prescribed since newer heart failure therapies became available, but it persists in some elderly patients with atrial fibrillation.

Chronic kidney disease: The relationship between CKD and potassium is complex. Early CKD may permit diuretic-related hypokalaemia; advanced CKD predisposes to hyperkalaemia. The KDIGO CKD guideline recommends monitoring potassium 3-monthly in CKD on diuretics or RAAS agents. Supplementation in CKD requires more careful monitoring to avoid overcorrection.

Perioperative patients: Hypokalaemia below 3.0 mmol/L is associated with increased perioperative arrhythmia risk. Most anaesthetists require correction before elective surgery. Inform the surgical team of any potassium results in the week preceding a procedure.

Hypokalaemic periodic paralysis: This familial autosomal-dominant condition or thyrotoxicosis-induced equivalent (common in young men of Asian descent) causes episodic flaccid paralysis triggered by carbohydrate loading, exercise, or stress. Correcting potassium too aggressively risks rebound hyperkalaemia as venom transiently shifts back extracellularly. Specialist-led low-dose potassium correction (5–10 mmol increments) is the approach.

When to escalate

Refer urgently (same-day or ambulance):

• Potassium below 2.5 mmol/L, or any level with ECG changes, cardiac arrhythmia, neuromuscular symptoms, or digoxin co-administration
• Respiratory muscle weakness or suspected descending paralysis
• Potassium that fails to correct despite adequate supplementation (review magnesium, consider aldosteronism)
• Suspected primary aldosteronism — endocrinology
• Eating disorder with severe electrolyte disturbance — eating-disorder team with psychiatric input
• Bartter or Gitelman syndrome suspected — nephrology or endocrinology
• Recurrent severe hypokalaemia without clear cause — specialist investigation

What this article is and is not

This is general health information drawn from current Australian general practice guidelines — Therapeutic Guidelines, Australian Medicines Handbook, NPS MedicineWise, and relevant specialist society guidance — for educational purposes. It is not personal medical advice and does not create a doctor–patient relationship. Specific treatment decisions, including medication choices and investigation sequencing, are made with your own GP and treating clinicians based on your individual circumstances.

For the best AU consumer information on electrolyte disturbances: HealthDirect and Better Health Channel.

---

Sources cited

1. Therapeutic Guidelines (eTG) — Renal and Endocrinology
2. Australian Medicines Handbook — Potassium chloride, magnesium, spironolactone monographs
3. NPS MedicineWise — Electrolyte management
4. PBS — Slow-K, Span-K, spironolactone listings
5. MBS Online — item 23 (standard GP consultation)
6. MBS Online — item 36
7. MBS Online — item 11700 (ECG)
8. MBS Online — item 965 (GP Chronic Disease Management Plan)
9. MBS Online — Eating Disorders Plan items 90250+
10. HealthDirect — Low potassium
11. Better Health Channel — Potassium
12. Kidney Health Australia
13. Endocrine Society — Primary Aldosteronism Clinical Practice Guideline 2016
14. BMJ Best Practice — Hypokalaemia
15. KDIGO — CKD electrolyte guidance